

# Prasugrel Treatment Patterns in Outpatient Settings in Germany, the United Kingdom, and France (H7T-MC-B011)

**First published:** 26/02/2014

**Last updated:** 30/03/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS5911

---

### Study ID

20445

---

### DARWIN EU® study

No

---

### Study countries

 France

 Germany

 United Kingdom

---

## Study description

This study is a retrospective, nonintervention cohort study aimed at describing the treatment patterns of prasugrel in outpatient practices in Germany and France using the IMS Disease Analyzer and in the United Kingdom (UK) using the IMS Disease Analyzer and the Clinical Practice Research Datalink (CPRD), formerly known as General Practice Research Database (GPRD), starting from launch to 3 years postlaunch

---

## Study status

Finalised

## Research institutions and networks

### Institutions

#### IMS Health

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

### Study institution contact

Asiimwe Alex [alex.asiimwe@lilly.com](mailto:alex.asiimwe@lilly.com)

Study contact

[alex.asiimwe@lilly.com](mailto:alex.asiimwe@lilly.com)

## Primary lead investigator

Asiimwe Alex

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 23/03/2009

Actual: 23/03/2009

---

### Study start date

Planned: 15/10/2009

Actual: 15/10/2009

---

### Data analysis start date

Planned: 10/02/2013

Actual: 10/02/2013

---

### Date of final study report

Planned: 09/04/2013

Actual: 09/04/2013

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Eli Lilly and Company and Daiichi Sankyo, Inc.

## Regulatory

## Was the study required by a regulatory body?

Yes

---

## Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

## Methodological aspects

### Study type

### Study type list

#### **Study topic:**

Disease /health condition

Human medicinal product

---

#### **Study type:**

Non-interventional study

---

#### **Scope of the study:**

Drug utilisation

#### **Data collection methods:**

Secondary use of data

---

#### **Main study objective:**

The objectives of the study were to provide descriptive statistics for the contraindication of TIA/stroke, maintenance dose, indication, patient

characteristics, co-morbidities, co-prescriptions, and patterns of drug usage in outpatient practices in France, the UK, and Germany

## Study Design

### **Non-interventional study design**

Cohort

## Study drug and medical condition

### **Medicinal product name, other**

Effient

---

### **Medical condition to be studied**

Acute coronary syndrome

## Population studied

### **Short description of the study population**

Patients who had the first prescription records of prasugrel, also referred to as prasugrel initiators, in the IMS Disease Analyzer and CPRD after prasugrel launch in France, the UK, and Germany. All prasugrel initiators in the IMS Disease Analyzer (France, the UK, and Germany) and CPRD were included.

---

### **Age groups**

- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

### **Special population of interest**

Other

---

### **Special population of interest, other**

Patients with acute coronary syndrome

---

### **Estimated number of subjects**

4106

## Study design details

### **Data analysis plan**

The study population consisted of patients who had at least 1 prescription record of prasugrel in France and Germany using the IMS Disease Analyzer and in the UK using the IMS Disease Analyzer and the CPRD. The date of the first prasugrel prescription recorded in the databases was defined as the index date. The patients were followed from the index date until death, transfer out of the practice, or the end of the study, whichever came first. Descriptive statistics (that is, mean SD, median, and quartile ranges for quantitative variables, and frequencies and percentages for qualitative variables) were provided for the contraindication of TIA/stroke, maintenance doses, body weight, patient demographic characteristics, co-morbidities, co-prescriptions, and patterns of drug usage in outpatient practices in respective countries.

## Documents

## Study results

[B011 03 Synopsis\\_Part1.pdf](#) (627.55 KB)

---

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s)

Clinical Practice Research Datalink

---

### Data source(s), other

IMS France, IMS Germany, IMS United Kingdom

---

### Data sources (types)

[Disease registry](#)

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

Unknown